Takeda (NYSE:TAK) reported a 67% lower relative risk of ulcerative colitis complications with ENTYVIO-based treatment targeting disease clearance rather than symptomatic remission alone.
Takeda (NYSE:TAK) and the Indonesian Government announced a landmark multi-year collaboration to enhance domestic health resilience and access to lifesaving therapies.
Axsome Therapeutics (NASDAQ:AXSM) announced on Wednesday, April 1, 2026, that it has acquired exclusive global rights to balipodect (formerly TAK-063) from Takeda Pharmaceutical Company.
Takeda (NYSE:TAK) announced that Japan’s Ministry of Health, Labour and Welfare approved ORZEYFUL (oveporexton) for adults with narcolepsy type 1, making it the company’s third global approval for the treatment.
Takeda (NYSE:TAK) said the U.S. FDA accepted its New Drug Application for zasocitinib under Priority Review for adults with moderate-to-severe plaque psoriasis.
